

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Final draft guidance**

(when no draft guidance was issued)

- |                             |  |
|-----------------------------|--|
| 1.                          | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| None identified at scoping. |  |

- |  |   |
|--|---|
| 2.   | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| The committee noted that Black ethnic groups have substantially higher mortality rates for endometrial cancer than other ethnic groups in the UK. The company said that access to innovative treatment on the NHS for late-stage disease can help address severe inequalities in survival outcomes by ethnicity or socio-economic deprivation. The committee considered equality issues and concluded that its recommendations do not affect people protected by the equality legislation differently to the wider population. |   |

|                            |   |
|----------------------------|---|
| 3.                         | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No other issues identified |   |

  

|    |   |
|----|---|
| 4. | Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No |   |

  

|    |  |
|----|--|
| 5. | Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No |  |

  

|     |  |
|-----|--|
| 6.  | Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality? |
| N/A |  |

  

|                      |   |
|----------------------|---|
| 7.                   | Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where? |
| Yes, in section 3.17 |   |

**Approved by Associate Director (name):** .....

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Issue date: April 2025

**Date:** [xx/xx/year]